GH1 and growth hormone-producing pituitary gland neoplasm: Although imatinib causes GH reduction in somatotropinoma cells (30%, P < 0.01), it was found to be less efficient than pasireotide (54%, P < 0.01) and octreotide (64%, P < 0.01; Supplementary Figure 4).